National Institutes of Health

Founded 1887


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 492
Average round size
The average size of a deal this fund participated in
Portfolio companies 48
Rounds per year 3.67
Lead investments 183
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 7
Key employees 1
Stages of investment

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Pharmaceutical

National Institutes of Health appeared to be the Corporate Investor, which was created in 1887. The leading representative office of defined Corporate Investor is situated in the Bethesda. The venture was found in North America in United States.

Besides, a startup needs to be aged 16-20 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Medical Device. Among the most popular portfolio startups of the fund, we may highlight 23andMe, Neurotrack, Second Sight. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2016. Considering the real fund results, this Corporate Investor is 31 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from National Institutes of Health is 1-5 millions dollars. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in 13-24 deals per year. Opposing the other organizations, this National Institutes of Health works on 18 percentage points less the average amount of lead investments.

The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the National Institutes of Health, startups are often financed by U.S. Department of Defense, New Enterprise Associates, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are National Science Foundation, National Institute of Allergy and Infectious Diseases, Small Business Innovation Research. In the next rounds fund is usually obtained by U.S. Department of Defense, Golden Angels Investors, Wisconsin Investment Partners.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of National Institutes of Health:
Typical Co-investors
National Institutes of Health is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after National Institutes of Health:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bharti Soft Bank United States, Belmont
JTBC United States, Los Angeles
Zimmerman Ventures United States, Milwaukee
Parkland Fuel Corporation Canada, Red Deer
Memorial Hermann Hospital United States, Houston
EMBL Ventures Germany, Heidelberg
Pumori Capital United States, Greenwich
Uncle Sam Loves Me, LLC United States, San Francisco
Halley Valley Venture -
WSB Holding -
Asia Green Fund China, Beijing Shi
Universe Ventures Russia, Moscow
Chunshan Pujiang China, Shanghai
Yinji Chuangtou China, Suzhou
Gruppo Campari United States, New York
edLABS -
Pumori Capital -
Alinea Capital Norway, Oslo
TQS Advisors -
Cabify Spain, Madrid

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Omnix Medical

Health Care
31 Aug 2021 Israel, Jerusalem

ImmunoBrain Checkpoint

Health Care
$5M27 Aug 2021 Israel, Ness Ziona

Eclipse Regenesis

Health Care
Medical Device
$1M26 Aug 2021 United States, Menlo Park


$1M25 Aug 2021 United States, Orlando

ID Genomics

Health Diagnostics
$300K24 Aug 2021 United States, Seattle

Praxis Bioresearch

$2M05 Aug 2021 United States, Sacramento

Feinstein Institute For Medical Research

Health Diagnostics
$2M02 Aug 2021 United States, Manhasset


Health Care
Medical Device
Monitoring Equipment
Therapeutic Devices
$9M30 Jun 2021 United States, Mountain View


Medical Device
$3M17 Jun 2021 United States, Worcester
CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm

– CytoAgents was awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year.
– The funding will accelerate the development of its lead drug candidate, GP1681, an investigational new drug that targets hypercytokinemia, more commonly known as “cytokine storm.”
– Scientific consensus is building that overwhelming inflammation and severe illness is triggered by a phenomenon known as cytokine storm, a severe form of cytokine release syndrome when an excessive immune response attacks the body.
– CytoAgents mission is to develop a broadly accessible treatment for multiple indications of high unmet need of cytokine storm, including for Cytokine Release Syndrome (CRS) in CAR T-cell therapy and in COVID-19 patients.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent National Institutes of Health?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: